GeoVax Labs Inc. (NASDAQ:GOVX) Short Interest Down 76.9% in June

GeoVax Labs Inc. (NASDAQ:GOVX) saw a significant decrease in short interest during the month of June. As of June 30th, there was short interest totaling 62,850 shares, a decrease of 76.9% from the June 15th total of 271,752 shares. Approximately 1.8% of the shares of the company are short sold. Based on an average daily volume of 436,362 shares, the days-to-cover ratio is presently 0.1 days.

Institutional Trading of GeoVax Labs

Hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC acquired a new position in GeoVax Labs during the 4th quarter worth $99,000. HRT Financial LP bought a new stake in shares of GeoVax Labs during the fourth quarter valued at about $31,000. Renaissance Technologies LLC acquired a new stake in GeoVax Labs in the fourth quarter worth about $104,000. Hudson Bay Capital Management LP acquired a new stake in GeoVax Labs in the third quarter worth about $47,000. Finally, Armistice Capital LLC bought a new position in GeoVax Labs in the 3rd quarter valued at about $253,000. Institutional investors own 6.09% of the company’s stock.

GeoVax Labs Stock Up 0.9%

NASDAQ GOVX traded up $0.01 on Friday, hitting $1.18. The stock had a trading volume of 87,745 shares, compared to its average volume of 356,370. GeoVax Labs has a one year low of $0.96 and a one year high of $23.10. The stock has a market cap of $4.09 million, a price-to-earnings ratio of -0.06 and a beta of 3.68. The company’s 50-day moving average is $1.65 and its two-hundred day moving average is $2.09.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings results on Wednesday, April 15th. The company reported $1.85 earnings per share for the quarter. On average, sell-side analysts anticipate that GeoVax Labs will post -8.69 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on GOVX shares. Wall Street Zen raised GeoVax Labs from a “sell” rating to a “hold” rating in a report on Sunday, June 21st. D. Boral Capital restated a “hold” rating on shares of GeoVax Labs in a research note on Thursday, April 16th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GeoVax Labs in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average target price of $150.00.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.